Abstract
The wearable cardioverter defibrillator: Still without a compelling indication
Highlights
The wearable cardioverter defibrillator (WCD) has recently been introduced as a therapy to reduce mortality in patients presumed to be at increased risk for sudden arrhythmic death
The WCD is being heavily advertised to temporarily “protect” patients presumed at increased risk for arrhythmic death, in particular patients early after acute myocardial infarction (MI) or with newly diagnosed dilated cardiomyopathy
Several randomized trials with the implantable implantable cardioverter defibrillator (ICD) [2,3,4] failed to show mortality reduction and these patients remain temporarily ineligible for device implantation for a period of 40 days or 90 days
Summary
The wearable cardioverter defibrillator (WCD) has recently been introduced as a therapy to reduce mortality in patients presumed to be at increased risk for sudden arrhythmic death. The WCD is being heavily advertised to temporarily “protect” patients presumed at increased risk for arrhythmic death (primary prevention), in particular patients early after acute myocardial infarction (MI) or with newly diagnosed dilated cardiomyopathy.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
